Canada: In search of genomic incentives

In a renewed quest for medical breakthroughs, the Canadian government recently committed $67.5-million for research into “personalized medicine.” This bold initiative promises faster, smarter and cheaper drug development by uncovering new targets, identifying patients likely to benefit from experimental therapies, and using molecular markers of disease to predict drug response.

Yet, personalized medicine follows on decades of efforts at plying molecular genetics toward drug development. To be sure, these approaches have borne fruit. But the process of developing cures remains painfully slow, error prone and costly. Despite steady increases in industry and public investment in research, the number of new drugs approved each year continues to decline.

Personalized medicine may very well fix a science that seems to be failing drug development. But perhaps we should be asking how drug development is failing science.

View the original article here: In search of genomic incentives

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend